secwatch.observer — SEC 8-K summary
======================================

Issuer:     Humacyte, Inc. (HUMA)
CIK:        0001818382
Form:       8-K
Filed at:   2022-11-10T23:59:59+00:00
Accession:  0001818382-22-000179
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Humacyte reports Q3 2022 net loss $25.3M, cash $171.7M, BLA filing for vascular trauma mid 2023
--------------------------------------------------------------------------------

- Cash $171.7M at Sep 30, 2022; net loss $25.3M for Q3; cash runway through 2024.
- BLA filing for HAV in vascular trauma anticipated mid 2023; 56 patients enrolled in V005 trial as of Oct 31.
- Phase 3 AV access trial nearing completion (227 of 240 enrolled); top-line results 1 yr after enrollment.
- Appointed Dr. Cindy Cao as Chief Regulatory Officer and Lt. Gen. C. Bruce Green to Board.
- Partnered with Diabetes Research Institute for Biovascular Pancreas program in type 1 diabetes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818382/000181838222000179/0001818382-22-000179-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818382/000181838222000179/huma-20221110.htm
  HTML page:      https://secwatch.observer/filing/0001818382-22-000179

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer